UnknownNot Applicable

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

China226 participantsStarted 2019-10-12

Plain-language summary

Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse effects on visual function. Intravitreal injection of vascular endothelial growth factor(VEGF) can induce short-term regression of retinal neovascularization(NV). The purpose is to assess and compare the efficacy and safety between intravitreal injection of conbercept and PRP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants of either sex aged 18 years or over.
✓. Diagnosis of diabetes mellitus (type 1 or 2).
✓. Best-corrected visual acuity (BCVA) in the study eye better than or equal to 30 Early Treatment Diabetic Retinopathy Study (ETDRS) letters
✓. PDR with no evidence of previous PRP.
✓. Media clarity, pupillary dilation and participant cooperation sufficient for adequate fundus photographs.

Exclusion criteria

✕. a glycated haemoglobin (HbA1c) level of more than 10%;
✕. Blood pressure \> 180/100 mmHg
✕. Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months
✕. dialysis or renal transplant
✕. Systemic anti-VEGF or pro-VEGF treatment within 6 months prior to randomization
✕. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years
✕. Traction retinal detachment involving the macula
✕. Exam evidence of neovascularization of the angle

What they're measuring

The primary outcome is mean visual acuity change(BCVA)

Timeframe: 12 months

Trial details

NCT IDNCT02911311

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12

View on ClinicalTrials.gov More Proliferative Diabetic Retinopathy trials